V.V. Fomin
Opening remark
|
3-3 |
Semiglazov V.F., Paltuev R.M., Semiglazov V.V., Dashyan G.A., Bessonov A.A., Penkov K.D., Vasilev A.G.
Nanotechnologies in diagnosis and treatment of malignant tumors
|
11-15 |
Semiglazov V.F.
Main results of clinical trials of 2009 in oncology
|
16-20 |
Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Ivanova O.A., Tabagua T.T., Shedrin D.E., Krivorotko P.V., Migmanova N.Sh., Grechuhina I.A.
Anticoagulants in venous thromboembolism and treatment in patients with malignant tumors
|
21-29 |
Koroleva I.A., Kopp M.V.
Prophylaxis of nausea and vomiting prevention in cytostatic treatment in adults
|
30-35 |
Bolotina L.V.
Modern possibility of bisphosphonates use in complex treatment of hormonedependent tumors
|
36-39 |
Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Paltuev R.M., Migmanova N.Sh., Shedrin D.E., Grechuhina I.A., Bessonov A.A., Penkov K.D., Merabishvili V.M.
Male breast cancer
|
40-45 |
Timofeev I.V.
First line therapy of metastaric renal carcinoma
|
46-49 |
Stilidi I.S., Arhiri P.P., Nikulin M.P., Mazurenko N.N., Anurova O.A., Medvedeva B.M.
Clinico-morphological prognostic factors in patients with gastrointestinal stromal tumors
|
50-55 |
Snegovoi A.V., Manzuk L.V.
Efficaсy of Heptral® in treatment of hepatotoxicity, induced by chemotherapy
|
56-61 |
Gorbunova V.A., Marenich A.F., Reutova E.V., Sheveleva L.P., Karaseva N.A., Bogdanova N.V., Uskov D.A., Hasanov R.Sh., Muhametshina G.Z., Tuzikov S.A., Horinko A.V., Ivanov R.A., Par V.I.
Paclitaxel and carboplatin in treatment of advanced non-small cell lung cancer: preliminary results of open prospective randomized clinical study
|
62-69 |
Krukenberg tumor
|
70-70 |